2021 Annual Meeting: 623. Mantle Cell, Follicular, and Other B-Cell Lymphomas: Clinical and Epidemiological: Evolution of Immunotherapeutic Regimens in B-cell Lymphomas

2021 Annual Meeting: 623. Mantle Cell, Follicular, and Other B-Cell Lymphomas: Clinical and Epidemiological: Follicular Lymphoma: Advances in Treatment Approaches

2021 Annual Meeting: 623. Mantle Cell, Follicular, and Other B-Cell Lymphomas: Clinical and Epidemiological: Front-line Induction Therapy and Novel Agents After Relapse

2021 Annual Meeting: 623. Mantle Cell, Follicular, and Other B-Cell Lymphomas: Clinical and Epidemiological: Targeted Therapy in Low Grade Lymphoma

2021 Annual Meeting: 624. Hodgkin Lymphomas and T/NK cell Lymphomas: Hodgkin Lymphoma Clinical Outcomes Data

2021 Annual Meeting: 624. Hodgkin Lymphomas and T/NK cell Lymphomas: Hodgkin Lymphoma Clinical Trials

2021 Annual Meeting: 624. Hodgkin Lymphomas and T/NK cell Lymphomas: T/NK Cell Lymphoma Frontline Clinical Trials

2021 Annual Meeting: 624. Hodgkin Lymphomas and T/NK cell Lymphomas: T/NK Cell Lymphoma Relapsed Therapy

2021 Annual Meeting: 626. Aggressive Lymphomas Prospective Therapeutic Trials: Challenging Populations

2021 Annual Meeting: 626. Aggressive Lymphomas Prospective Therapeutic Trials: Novel Agents and Combinations

2021 Annual Meeting: 627. Aggressive Lymphomas: Clinical and Epidemiological: Clinical Management of Aggressive B cell NHL

2021 Annual Meeting: 627. Aggressive Lymphomas: Clinical and Epidemiological: Population data for Aggressive NHL Management

2021 Annual Meeting: 627. Aggressive Lymphomas: Clinical and Epidemiological: Real World evidence for CAR-T Management I

2021 Annual Meeting: 627. Aggressive Lymphomas: Clinical and Epidemiological: Real World evidence for CAR-T Management II

2021 Annual Meeting: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational I

2021 Annual Meeting: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational II

2021 Annual Meeting: 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Mechanisms of resistance and expanded therapies

2021 Annual Meeting: 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Progress with response prediction and TKI discontinuation

2021 Annual Meeting: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Non-JAK inhibitor Therapies for Myelofibrosis

2021 Annual Meeting: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Novel Therapies for MPNs and JAK inhibitors for Myelofibrosis

2021 Annual Meeting: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Risk Stratification and Prognostication

2021 Annual Meeting: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Transplantation, COVID-19 and Biology Insights

2021 Annual Meeting: 636. Myelodysplastic Syndromes—Basic and Translational: Clonal Progression and Aberrant Erythropoiesis in Splicing Factor-Mutant MDS

2021 Annual Meeting: 636. Myelodysplastic Syndromes—Basic and Translational: Genomics and Novel Targets in MDS

2021 Annual Meeting: 637. Myelodysplastic Syndromes – Clinical and Epidemiological: Low Risk Myelodysplastic Syndrome Prognosis and Treatment

2021 Annual Meeting: 637. Myelodysplastic Syndromes – Clinical and Epidemiological: Treatment of High Risk Myelodysplastic Syndrome

2021 Annual Meeting: 641. Chronic Lymphocytic Leukemias: Basic and Translational: Molecular Dissection of CLL and Richter's Transformation

2021 Annual Meeting: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological I

2021 Annual Meeting: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological II

2021 Annual Meeting: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Combination Small Molecules